TABLE 3

Between-group differences in change in primary and secondary outcomes from baseline to 3 and 6 months (n=153)

InterventionUsual care control
MeanseMeanseMean differencep-value#
Primary outcome
 Δ6MWD
  3 months23.869.5827.589.51−3.720.686
  6 months25.149.6137.419.63−12.270.189
Secondary outcomes
 ΔDaily step-count
  3 months645.95391.97−385.78411.451031.730.005
  6 months672.90392.48−639.38415.311312.28<0.001
 ΔSGRQ-TS
  3 months−14.633.59−13.863.22−0.780.833
  6 months−13.053.59−15.133.22−28.180.572
 ΔmMRC dyspnoea
  3 months−0.170.210.070.21−0.250.225
  6 months−0.060.210.000.21−0.050.799
 ΔBCKQ
  3 months1.441.810.761.660.690.692
  6 months0.921.811.971.66−1.050.544
 ΔMOS-SS
  3 months−4.934.24−1.014.30−3.920.279
  6 months0.554.254.384.36−3.830.293
Acute exacerbationsn%n%Differencep-value
Total
 3 months2336−10.563
 6 months7125920.676
With hospitalisation
 3 months121200.940
 6 months1236−20.260

Acute exacerbations are displayed as number and percentage of participants from study sample (n, %). Δ: change; 6MWD: 6-min walk distance (metres); SGRQ-TS: St. George's Respiratory Questionnaire Total Score; mMRC: modified Medical Research Council; BCKQ: Bristol COPD Knowledge Questionnaire; MOS-SS: Medical Outcomes Study Social Support survey. #: based on linear mixed-effect model adjusting for group, 3- and 6-month indicators, group×time interaction indicators, site, age, mean forced expiratory volume in 1 s % predicted and rurality. : obtained from Chi-square test.